Skip to content
Research Article Open access CC BY 4.0

Lights and Shadows of Rituximab in Dermatology

Ashok Kumar, Geo Danny, Sane Roja Renuka, Arisha Salam

Journal of Pharmaceutical Research International · pp. 179–187 · Published 21 Dec 2021

10.9734/jpri/2021/v33i60B34602

Abstract

Rituximab is a CD 20 monoclonal antibody drug used in various spectrum of diseases today. It has proven to be a boon, especially in the field of dermatology. Although Rituximab was initially introduced as a novel method to treat B-cell Non Hodgkin Lymphoma, its use has rapidly expanded to include a number of other Lymphomas and Autoimmune diseases.This review is to give a bird’s eye view of updates on rituximab. Conclusion: With its horizons expanding in dermatology, and with better information regarding its efficacy and safety profile, Rituximab has now become an approved first‑line therapy for pemphigus. In conclusion, Rituximab has proven to be a substantial boon for dermatologists in difficult to treat cases.

Monoclonal antibodies CD20 Lymphoma protocol Rheumatoid arthritis protocol non-Hodgkin’s lymphoma (NHL) pemphigus vulgaris (PF) Pemphigus foliaceous (PF) RTX (Rituximab)

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

12

Page views

0

PDF downloads

2

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.